Assetmark Inc. Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Assetmark Inc. boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 27.5% in the third quarter, Holdings Channel reports. The institutional investor owned 6,667 shares of the medical equipment provider’s stock after acquiring an additional 1,437 shares during the quarter. Assetmark Inc.’s holdings in Hologic were worth $543,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of HOLX. Empowered Funds LLC bought a new stake in shares of Hologic during the 1st quarter worth $234,000. Bleakley Financial Group LLC increased its position in shares of Hologic by 18.3% during the first quarter. Bleakley Financial Group LLC now owns 5,412 shares of the medical equipment provider’s stock valued at $422,000 after buying an additional 836 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Hologic by 15.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 278,181 shares of the medical equipment provider’s stock worth $21,687,000 after acquiring an additional 36,898 shares in the last quarter. Banco Santander S.A. bought a new stake in Hologic during the first quarter worth about $344,000. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Hologic by 0.4% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 292,378 shares of the medical equipment provider’s stock worth $22,490,000 after buying an additional 1,136 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HOLX. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday. Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Royal Bank of Canada upped their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Finally, UBS Group raised their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Up 1.4 %

HOLX stock opened at $78.60 on Friday. The company’s 50 day moving average price is $80.71 and its 200 day moving average price is $78.23. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The firm has a market capitalization of $18.26 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.89 earnings per share. On average, equities research analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.